INFU Stock Analysis: Buy, Sell, or Hold?
INFU - InfuSystem Holdings, Inc.
$8.61
0.40 (4.87%)
▲
5d:
-4.01%
30d:
-15.59%
90d:
+16.04%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When INFU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INFU appears deeply undervalued. Market expects -7.6% annual earnings decline despite 124% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: INFU appears deeply undervalued. Market expects -7.6% annual earnings decline despite 124% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$13.22
34.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INFU is currently trading at $8.61, which is considered oversold relative to its 30-day fair value range of $9.01 to $10.53. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.5) compared to its historical average (19.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.6% over the next few years. This pessimistic expectation contrasts with the company's recent 123.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INFU is in a uptrend. Immediate support is located at $8.04, while resistance sits at $10.70. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.88 (+72.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INFU is in a uptrend. Immediate support is located at $8.04, while resistance sits at $10.70. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.88 (+72.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.01 -
$10.53
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 72.8% below Wall St target ($14.88)
Trading Range Analysis
30-Day Trading Range
$9.01 -
$10.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.04
Resistance Level
$10.70
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.51
Wall Street Target
$14.88
(+72.8%)
Revenue Growth (YoY)
7.0%
Earnings Growth (YoY)
123.9%
Profit Margin
4.6%
Valuation Discount vs History
-7.6% cheaper
PE vs Historical
15.5 vs 19.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.6%
(market-implied from PE analysis)
1-Year Target
$7.96
(-8%)
2-Year Target
$7.35
(-15%)
3-Year Target
$6.79
(-21%)
3-Yr Target (if PE normalizes)
(PE: 16→20)
$8.63
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 26.9%)
$24.97
(+190%)
Base:
(SPY PE: 15.5, Growth: 26.9%)
$17.58
(+104%)
Bear:
(PE: 13.2, Growth: 26.9%)
$14.94
(+74%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 22.81 | Current EPS (TTM): $0.36
Bull Case
$13.92
(+62%)
Analyst growth 54.2%, PE expands to 25.1
Base Case
$12.66
(+47%)
Market implied 54.2%, PE stable at 22.8
Bear Case
$5.58
(-35%)
Severe decline -20.0%, PE contracts to 19.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.5 to 19.7
Stabilization Target:
$10.93
(+27.0%)
PE Expansion Potential:
+27.0%
Share & Embed Analysis
Last updated: May 14, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INFU showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Barry G Steele
BUY
2064 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$392 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$84 | 60 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 58 HOLD |
